Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is defined by the World Health Organization (WHO) Classification as a heterogeneous entity, encompassing morphologic and genetic variants, and variable clinical presentations and outcomes \[[@B1]\]. It accounts for 80% of aggressive lymphomas \[[@B2]\]. International Prognostic Index (IPI) is currently used to predict the prognosis in DLBC \[[@B3]\], but its role is limited\[[@B4]\]. Molecular subtypes of germinal center B cell-like (GCB) and non-germinal center B cell-like (non-GCB) DLBCL subtypes are proposed to stratify the prognosis of DLBCL in addition to the IPI score \[[@B5]-[@B7]\], but the application of Rituximab reduced the prognostic difference between the two subtypes \[[@B8],[@B9]\]. More prognostic markers should be identified for DLBCL.

The Signal Transducers and Activators of Transcription (STAT) family members play important roles in transcriptional regulation and signal transduction, in which STAT3 plays a critical role in regulation of cell proliferation and survival \[[@B10]\] and is a critical transcription activator in angiogenesis \[[@B11]\]. Hypermethylation silencing of SOCS (the Suppressor of Cytokine Signaling) genes leads to reactivation of STAT pathway, resulting in the resistance to ABT-869, a promising multi-targeted tyrosine kinase inhibitor \[[@B12]\]. STAT pathway also triggers the activity of receptor-associated Janus kinase (JAK) family members and cross-talks with the nuclear factor-κB (NF-κB) pathway, which is an important molecular pathogenesis of lymphoma \[[@B13]\]. Thus the STAT family has been actively studied as one of molecular targets for anti-neoplastic therapy \[[@B14]\].

Expression of STAT3 in DLBCL subtypes may be variable according to *in vitro*studies \[[@B15],[@B16]\]. The cell line studies showed that the activated B cell-like (ABC) DLBCL had the highest level of STAT3 mRNA, roughly 2-fold higher than that in the GCB DLBCL\[[@B15],[@B16]\]. However, the STAT3 expression and its prognostic value in different subtypes of DLBCL tumors were not investigated. In the study, we investigated the expression level and frequency of STAT3 in DLBCL tumors, the difference of STAT3 expression in different DLBCL subtypes, and its prognostic value in DLBCL patients.

Materials and methods
=====================

Patients
--------

Seventy-four consented patients with DLBCL in the Beijing Cancer hospital from 2001-2007 were studied. In 58 patients, 27 cases were treated with R-CHOP and 31 cases with CHOP as first-line regimens. The clinical research protocol was approved by our Institutional Review Board (IRB). Archived formalin-fixed and paraffin-embedded tumor tissues were obtained from our Department of Pathology.

Immunohistochemical analysis (IHC)
----------------------------------

4 μm thick sections were mounted on APES-coated slides. After dewaxing in xylene and rehydrating in a gradient concentration of ethanol, the slides were immersed in methanol containing 0.3% hydrogen peroxide for 15 minutes to block endogenous peroxidase activity. All slides were pretreated with an antigen retrieval method by heating the slides in an autoclave in citrate buffer (10 mM, pH 6.0) for 90 seconds except those stained for P-STAT3. EDTA-Tris buffer (1 mM, pH 9.0) was used for pretreating before P-STAT3 staining. After rinsing in TBS (pH7.6), the specimens were incubated for 2 h at 37°C with anti-STAT3 antibody (sc-7179 rabbit polyclonal antibody, Santa Cruz Biotechnology) for STAT3, anti-P-STAT3 antibody (9145, rabbit monoclonal antibody, Cell Signaling Technology) for P-STAT3^Tyr705^, and antibodies for BCL6, CD10, MUM-1 (Santa Cruz Biotechnology). Subsequently, all slides were incubated with Envision HRP antibody working fluid (Dako Company) for 30 minutes at 37°C, and then developed with DAB-H~2~O~2~solution (Dako Company). The cell nuclei were stained with Meyer\'s hemotoxylin. The normal tonsil tissue was used as a negative control and breast cancer tissue stained positive was used as a positive control for STAT3 and P-STAT3 in all experiments. For technical details, see the manufacturer\'s instructions for each reagent.

IHC staining was evaluated by two independent experienced pathologists, who were blinded to the clinical data. As for the nuclear staining, at least 100 tumor cells per specimen were counted and only specimens showing moderate to strong immunoreactivity were considered positive. Staining was considered strong positive when \> 75% of tumor cell nuclei were stained positive for STAT3 and \> 30% of tumor cell nuclei for P-STAT3. Specimens stained positive for STAT3 ≤ 75% and ≤ 30% for P-STAT3 were considered weak immunoreactivity.

Statistics
----------

The Chi-square test was used to analyze the consistence of expressions of STAT3 in nucleus and P-STAT3. Correlation analysis of the STAT3 expression and the P-STAT3 level with clinicopathological variables was performed by two-sided Chi-square test. Kaplan-Meier method was used to estimate difference of OS. OS was defined as the time from diagnosis to death or the last follow-up. The Cox regression model was used to evaluate the prognostic value. The statistical software SPSS16.0 was used for all the statistical analysis.

Results
=======

Patient characteristics
-----------------------

All patients had complete follow-up information from the Tumor Registry Office in our hospital. The clinicopathological characteristics are summarized in Table [1](#T1){ref-type="table"}. Fifty five patients were younger than 60 years old. Male and female patients were 30 and 44, separately. Twenty nine patients were diagnosed with B symptoms, 50 patients had stage III-IV diseases and 50 patients were diagnosed with the non-GCB subtype.

###### 

Clinicopathological parameters and their correlations with STAT3 nuclear expression

  Clinical Parameters   *No.\#*   Nuclear Staining   *P Value*   Clinical Parameters   *No.\#*              Nuclear Staining   *P Value*        
  --------------------- --------- ------------------ ----------- --------------------- -------------------- ------------------ ----------- ---- -------
  Gender                                                                               Stage                                                    
   Male                 30        20                 10          0.165                  I\~II               24                 18          6    0.582
   Female               44        35                 9                                  III\~IV             50                 37          13   
  Age                                                                                  IPI                                                      
   \< 60                55        43                 12          0.161                  0\~2                48                 39          9    0.099
   ≥ 60                 19        12                 7                                  3\~4                22                 14          8    
  B symptoms                                                                           Bulky mass                                               
   positive             29        23                 6           0.306                  ≥ 10 cm             9                  6           3    0.440
   negative             45        32                 13                                 \< 10 cm            55                 47          16   
  LDH                                                                                  Molecular subtypes                                       
   positive             28        19                 9           0.235                  GCB                 24                 21          3    0.061
   negative             46        36                 10                                 non-GCB             50                 34          16   
  β2-MG                                                                                Treatment regimens                                       
   positive             46        34                 12          0.513                  CHOP                31                 22          9    
   negative             17        12                 5                                  R-CHOP              27                 19          8    
  ESR                                                                                                                                           
   positive             38        28                 10          0.406                                                                          
   negative             29        23                 6                                                                                          

STAT3 expression
----------------

Among the 74 patients, 66 cases (89.19%) had the STAT3 expression, including 19 cases (25.7%) with strong nuclear staining of STAT3, and 24 cases (32.4%) with strong nuclear staining of P-STAT3. Representative staining outcomes were shown in Figure [1](#F1){ref-type="fig"}. There existed a consistence between the STAT3 expression and the P-STAT3 level (*P*= 0.001), indicating the reliability and accuracy of our IHC analysis (Table [2](#T2){ref-type="table"}).

![**STAT3 expression and P-STAT3 level in DLBCL (A) negative nuclear staining of STAT3, (B) negative nuclear staining of P-STAT3, (C) weak nuclear staining of STAT3, (D) weak nuclear staining of P-STAT3, (E) strong nuclear staining of STAT3, (F) strong nuclear staining of P-STAT3**.](1756-8722-4-31-1){#F1}

###### 

Relationship between the STAT3 expression and the P-STAT3 level

                                  STAT3 expression in nucleus   Total   *P Value*   
  ------------- ----------------- ----------------------------- ------- ----------- -------
  **P-STAT3**   Low positive      43                            7       50          
                Strong positive   12                            12      24          0.001
  **Total**                       55                            19      74          

Correlation between the nuclear expression of STAT3 and clinicopathological parameters
--------------------------------------------------------------------------------------

We observed the associations of the STAT3 nuclear expression with IPI score and molecular subtypes, but no statistical significances were reached (*P*= 0.099 and *P*= 0.061, respectively). No association was found between the STAT3 nuclear expression and other factors, including B symptoms, age of onset, clinical stage, and erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), and tumor size (Table [1](#T1){ref-type="table"}).

Association between the nuclear expression of STAT3 and overall survival
------------------------------------------------------------------------

Kaplan-Meier analysis showed that strong STAT3 nuclear expression was correlated with poorer OS (*P*= 0.005) (Figure [2](#F2){ref-type="fig"}). Other factors such as serum LDH level, clinical stage, B symptoms, tumor size, and IPI score were also shown to be correlated with OS (data not shown) as reported in other studies, which confirmed our data is reliable. A forward stepwise multivariate Cox model analysis, incorporating the above factors, demonstrated that the nuclear expression of STAT3 (*P*= 0.001), LDH level (*P*= 0.002) and tumor size (*P*= 0.025) were independent prognostic factor for OS.

![**Kaplan-Meier curve of overall survival (OS) using STAT3 nuclear expression**.](1756-8722-4-31-2){#F2}

To analyze the prognostic implication of STAT3 in term of Rituximab therapy, we stratified all patients into two subgroups, the CHOP subgroup and the R-CHOP subgroup. In CHOP subgroup, high nuclear expression of STAT3 predicted poor survival (*P*= 0.001). In R-CHOP subgroup, 2 of 19 cases died of DLBCL in low STAT3 cohort and 3 of 8 cases died in high STAT3 cohort. No significant association was observed between the expression of STAT3 and prognosis (*P*= 0.216) in the R-CHOP subgroup. But the survival curve showed that high STAT3 expression indicated poor OS in the first 40 months. Thus, it needs to increase the sample size to confirm this result (Table [3](#T3){ref-type="table"}, Figure [3](#F3){ref-type="fig"}).

###### 

Correlation of STAT3 nuclear expression with overall survival

  treatment   STAT3   OS   *P*   
  ----------- ------- ---- ----- -------
  CHOP        Low     1    21    0.001
              High    3    6     
  R-CHOP      Low     2    17    0.216
              High    3    5     

![**Kaplan-Meier curve of overall survival (OS) in patients with different treatment regimens using STAT3 nuclear expression**. (A) Patients received the CHOP regimen; (B) Patients received the R-CHOP regimen.](1756-8722-4-31-3){#F3}

Discussion
==========

Lam LT\[[@B15]\] et al. reported that activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) had higher level of STAT3 mRNA than that in GCB-DLBCL. Detection with immunohistochemistry \[[@B15]\] showed that slightly more cases with high nuclear expression of STAT3 were observed in the non-GCB DLBCL group and the high expression rates were 12.5% and 32.4% in GCB and non-GCB subtypes, respectively. However, no statistical significance was found. This is most likely due to the small sample size. Our study showed that the frequency of high nuclear expression of STAT3 in DLBCL was 25.7% with 12.5% in GCB subgroup and 32% in non-GCB subgroup, but not reaching significance (*P*= 0.061).

Lam LT et al. \[[@B15]\] also demonstrated that high STAT3 expression in ABC-DLBCL patients correlated with inferior overall survival, but not with GCB-DLBCL patients. However, STAT3-high and STAT3-low subsets within ABC-DLBCL did not differ in prediction of overall survival. Our study showed that high nuclear expression of STAT3 in DLBCL possibly correlated with poor overall survival, especially in patients receiving CHOP regimen. This poor outcome may be explained at least in part by the multiple cellular functions of STAT3, which is a critical component of diverse signal transduction pathways\[[@B15],[@B17],[@B18]\]. STAT3 regulates the expression of a number of genes (e.g. survivin, bcl-xl, mcl-1) that modulate cell survival, differentiation, and proliferation (e.g. c-myc, cyclin D1, p21, cyclin E), invasion and metastasis (e.g. matrix metalloproteinase-9 and 2)\[[@B19]\], and angiogenesis (e.g. vascular endothelial growth factor) \[[@B11],[@B20],[@B21]\]. STAT3 can restrain anti-tumour immune responses \[[@B22]-[@B27]\] and regulate key cancer-promoting inflammatory mediators, which can initiate or promote oncogenic transformation, and genetic and epigenetic changes in malignant cells \[[@B28],[@B29]\].

Our study also demonstrated the possibility of using immunohistochemistry to detect STAT3 expression in routine pathologic specimens, which may enable us conveniently to identify DLBCL cases with poor clinical outcome, and subsequently guides us to adopt more intensive treatment for those patients.

Since STAT3 plays a critical role in tumor initiation and progression, inhibition of STAT3 activation would be an effective approach for cancer prevention and treatment. Our findings may provide a basis for the application of STAT3 inhibitors in the future.
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